Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the global and segmental hepatic uptake and excretion of Gd-EOB-DTPA on Gd-EOB-DTPA-enhanced liver MRI correlates with standard liver function test results in the patients with Hepatocellular Carcinoma (HCC) before major hepatic resection or radiofrequency ablation (RFA).

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborators: Asan Medical Center; Bayer; Chonnam National University Hospital; Seoul St. Mary's Hospital
• Treatments: Edetic Acid; Liver Extracts; Pentetic Acid

Criteria

Inclusion Criteria:

1. Patients with the diagnosis of HCC based on noninvasive diagnostic criteria of HCC proposed by 2010 AASLD

2. Surgical resection of hepatic resection greater than 2 Couinaud segments (including total hepatectomy for transplantation) or radiofrequency ablation is planned

3. Patients who provided the informed consent

Exclusion Criteria:

1. Patients younger than 18 yrs old

2. Patients who received hepatic surgery prior to this study

3. Patients who underwent TACE or RFA for greater than 2 segments within 3 months prior to this study

4. Patients who received radiation treatment including the liver or systemic chemotherapy

5. Patients who underwent contrast enhanced liver MRI within 3 days prior to this study

6. Patients with severe renal dysfunction (Cr .2.5 mg/dL or GFR < 30mL/min)

7. Patients with hypersensitivity to gadolinium

8. Patients with uncorrectable hypokalemia

9. Pregnant women, or reproductive age women who will not agree with contraception during this study period.

10. Patients with mental disorder which will interfere with voluntary agreement

11. Patients who have any contraindication to MRI (cardiac pacemaker, ferromagnetic implants, etc.)

12. Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the completion of the study.